<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>FK228 is a novel antitumor <z:chebi fb="0" ids="23643">depsipeptide</z:chebi> that inhibits <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylases and restores the expression of genes aberrantly suppressed in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells </plain></SENT>
<SENT sid="1" pm="."><plain>This agent was shown to have broad antitumor activity in preclinical studies, and is currently under phase I/II evaluations </plain></SENT>
<SENT sid="2" pm="."><plain>Because of its wide spectrum of actions, it is reasonable to consider the combination with other anticancer drugs in clinical application </plain></SENT>
<SENT sid="3" pm="."><plain>We studied the cytotoxic interaction of FK228 in combination with conventional antileukemic agents using human promyelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> HL60, <z:e sem="disease" ids="C0856536" disease_type="Neoplastic Process" abbrv="">Philadelphia chromosome-positive</z:e> (Ph(+)) <z:hpo ids='HP_0005506'>chronic myelogenous leukemia</z:hpo> KU-812, T-cell lymphoblastic <z:hpo ids='HP_0001909'>leukemia</z:hpo> MOLT3 and Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> Raji cell lines </plain></SENT>
<SENT sid="4" pm="."><plain>For the combination of FK228 and <z:chebi fb="0" ids="45783">imatinib</z:chebi>, Ph(+) <z:hpo ids='HP_0001909'>leukemia</z:hpo> KU812, K562 and <z:chebi fb="15" ids="48347">TCC</z:chebi>-S cell lines were used </plain></SENT>
<SENT sid="5" pm="."><plain>The cells were exposed simultaneously to FK228 and other agents for 4 days </plain></SENT>
<SENT sid="6" pm="."><plain>Cell growth inhibition was determined by using <z:chebi fb="0" ids="53233">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</z:chebi> (<z:chebi fb="0" ids="53233">MTT</z:chebi>) assay </plain></SENT>
<SENT sid="7" pm="."><plain>We used the isobologram method of Steel and Peckham to evaluate the cytotoxic interaction at the concentration of drugs that produced 80% cell growth inhibition (IC(80)) </plain></SENT>
<SENT sid="8" pm="."><plain>FK228 showed an additive effect with <z:chebi fb="0" ids="28680">cytarabine</z:chebi>, <z:chebi fb="2" ids="31355">carboplatin</z:chebi>, <z:chebi fb="0" ids="28748">doxorubicin</z:chebi>, <z:chebi fb="0" ids="4911">etoposide</z:chebi>, 4-<z:chebi fb="0" ids="29792">hydroperoxy</z:chebi>-<z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="1" ids="50667">6-mercaptopurine</z:chebi> and SN-38 (active metabolite of irinotecan) in <z:hpo ids='HP_0000001'>all</z:hpo> cell lines studied </plain></SENT>
<SENT sid="9" pm="."><plain>FK228 with <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and <z:chebi fb="0" ids="28445">vincristine</z:chebi> showed an antagonistic effect in three and one of the four cell lines, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>FK228 was additive with <z:chebi fb="0" ids="45783">imatinib</z:chebi> in <z:hpo ids='HP_0000001'>all</z:hpo> three Ph(+) <z:hpo ids='HP_0001909'>leukemia</z:hpo> cells </plain></SENT>
<SENT sid="11" pm="."><plain>Our findings suggest that FK228 is a promising candidate for combining with most anticancer agents except for <z:chebi fb="0" ids="44185">methotrexate</z:chebi> and <z:chebi fb="0" ids="28445">vincristine</z:chebi>, which produce suboptimal effects </plain></SENT>
</text></document>